Zachary D. Wallen

Elucidating the dysbiotic features of gut microbiome, interaction with the human genome, and utility as a biomarker for treatment of Parkinson disease.

This study identifies dysbiotic gut microbiome features in Parkinson's disease, links them to genetic variants, and proposes microbiome-based biomarkers for targeted treatment.

Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease

The paper develops microbiome-based biomarkers to identify suitable patients for microbiome-based therapies in Parkinson's disease, showing that not all patients have dysbiotic microbiomes and that dysbiotic microbiomes vary in features.

Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms

This study investigates the gut microbiome's role in Parkinson's disease using metagenomics, finding widespread dysbiosis and associations with disease mechanisms.

Comparison study of sixteen differential abundance testing methods using two large Parkinson disease gut microbiome datasets

This study compares 16 differential abundance methods on two Parkinson disease gut microbiome datasets, finding varied results and highlighting the need for replication across methods and datasets.

Human-genome gut-microbiome interaction in Parkinson's disease

The paper shows that genetic variants at the alpha-synuclein locus influence gut microbiome dysbiosis in Parkinson's disease.

Large-scale association analyses identify host factors influencing human gut microbiome composition

The paper identifies 31 host genetic loci influencing gut microbiome composition through GWAS and suggests causal effects in inflammatory diseases.

Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens

This study identifies three clusters of gut microbiota associated with Parkinson's disease, including overabundance of opportunistic pathogens.